New drug combo aims to save kidneys in pelvic cancer patients

NCT ID NCT07233252

Recruiting now Disease control Sponsor: Tianjin Medical University Second Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase II trial tests whether a combination of tislelizumab (an immunotherapy) and nab-paclitaxel (a chemotherapy drug) can treat renal pelvic cancer while allowing patients to keep their kidney. About 35 adults with early-stage cancer will receive the drugs, and if the tumor shrinks enough, they may also get laser or freezing treatment to remove any remaining cancer. The main goal is to see if patients can avoid kidney removal for at least one year.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tislelizumab and nab-paclitaxel
What this could lead to: If successful, this could offer a way to treat renal pelvic cancer without removing the kidney, preserving kidney function.
What could go wrong: This is a small, early-phase trial with only 35 participants, so results may not apply widely. The combination therapy may cause side effects, and not all patients will respond well.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for KIDNEY-SPARING are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

renal pelvis carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

KIDNEY-SPARING NAB-PACLITAXEL PD-1 INHIBITOR RENAL PELVIC CARCINOMA TISLELIZUMAB

Contacts and locations

Locations

The Second Hospital of Tianjin Medical University
RECRUITING

Tianjin, Outside U.S., 300211, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.